(ICCC)

Reporting relationship: President & CEO, Director
Issuer ticker: ICCC
Reported as of: 31 Jan 2022
Net transaction value: +$8,150
SEC form: 4
Accepted by SEC: 09 Feb 2022, 15:58:28 UTC
Next SEC filing: 24 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/Michael F Brigham

Key filing fact

Michael F. Brigham filed Form 4 for IMMUCELL CORP /DE/ (ICCC) on 09 Feb 2022.

Key facts

This page summarizes Michael F. Brigham's Form 4 filing for IMMUCELL CORP /DE/ (ICCC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Feb 2022, 15:58.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$8,150.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICCC transaction Derivative

Incentive Stock Options (Right to buy)

Award

Transaction value: $8,150
Shares: +1,000
Change %
Price: $8.15
Shares after: 1,000
Date: 31 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000
Exercise price: $8.15
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option grant is made subject to the reservation of more shares for the Company's 2017 Stock Option Plan by vote of stockholders at the 2022 Annual Meeting of the Company.